Merck to acquire Immune Design for $300M
The deal, expected to close in the second quarter of this year, would bolster Merck's therapeutic vaccine capabilities, an analyst wrote.
presented by
Immune Design
The deal, expected to close in the second quarter of this year, would bolster Merck's therapeutic vaccine capabilities, an analyst wrote.